• Profile
Close

Prolongation of tumor volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine-refractory differentiated thyroid cancer selected for molecular targeted therapy

Clinical Endocrinology Feb 09, 2019

Sabra MM, et al. - Researchers analyzed the data to evaluate the ability of molecular targeted therapy (MTT) to influence tumor volume doubling time (TVDT) and disease-specific survival (DSS) in cases with lung metastasis from radioactive iodine-refractory progressive thyroid cancer. They recorded the median survival of 2.9 years after MTT start. They noticed a prolonged lung average tumor volume doubling time (midDT) > 3 years in 75% of cases with baseline midDT < 1 year and 100% of patients with midDT 1-3 years. In patients with rapidly progressive thyroid cancer, they found the median survival of 4.5 years in those with MTT- achieved midDT > 3 years, as compared to 2.3 years and 0.7 years in those with MTT-achieved midDT of 1-3 years and MTT-achieved midDT < 1year respectively.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay